期刊文献+

TSGF、CEA在治疗非小细胞肺癌中的临床意义 被引量:1

The Clinic Significance of TSGF,CEA in Non-small-cell Lung Cancer
下载PDF
导出
摘要 目的:本研究旨在观察TSGF(肿瘤特异性生长因子)、CEA(癌胚抗原)在非小细胞肺癌(NSCLC)后程放疗同步化疗中的变化,评价以上肿瘤标志物的临床价值。方法:40例NSCLC患者均进行后程照射同步两周期化疗,分别于治疗前以及治疗完成后4周进行TSGF以及多肿瘤标志物蛋白芯片检测。结果:TSGF、CEA在治疗开始时的阳性率分别为62%、57%,治疗后各观测指标均显著性下降(P<0.05),尤其对于达CR的患者。对于治疗有效的患者,CEA阴性患者的近期生存期显著长于阳性患者。结论:NSCLC患者后程放疗同步TP方案化疗中,对于治疗有效患者TSGF、CEA的下降与影像学资料具有一致性;并且CEA可以作为预后指标。 Objective: Our research is to observe the change of TSGF, CEA in the late-course radiotherapy combined with chemotherapy in non-small-cell lung cancer, and to evaluate the clinical significance of the above tumor makers. Methods: Thirty-eight NSCLC patients were treated by late-course radiotherapy combined with two cycle chemotherapy, tested TSGF and multi-tumor maker protein chip at the beginning and weeks after therapy. Results: The positive rate of TSGF, CEA is 62%, 57% in the observed objectives at the therapy beginning. It indicates significant reducing change of TSGF and CEA after therapy compared with the indexes at the therapy beginning ( P 〈 0.05 ), especially to the patients that reach CR and PR curative effect. To the CR and PR patients that express negative CEA indicate long recent survival than positive patients ( P 〈 0. 05 ). Conclusion: To the lung cancer patients treated by late-course radiotherapy combined with TP chemotherapy who reach CR curative effect, the decreasing of TSGF keep consistence to the emerge change. CEA can be seemed as the prognosis indexes.
作者 敖金娥 杨婉
出处 《中国医药导刊》 2007年第4期346-348,共3页 Chinese Journal of Medicinal Guide
关键词 非小细胞肺癌 TSGF CEA 放疗 化疗 NSCLC Tumor marker Radiotherapy Chemotherapy
  • 相关文献

参考文献6

二级参考文献20

  • 1[1]Schneider J, Bitterlich N, Velcovsky HG, et al. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer[J]. IntJ Clin Oncol, 2002, 7(3): 145~151 被引量:1
  • 2[2]Trape J, Buxo J, Perez de Olaguer J, et al. Tumor markers as prognostic factors in treated non-small cell lung cancer [J]. Anticancer Res, 2003, 23(5b): 4277~4281 被引量:1
  • 3[3]Muley T, Dienemann H, Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage Ⅰ NSCLC[J]. Anticancer Res, 2003, 23(5b): 4085~4093 被引量:1
  • 4[4]Buccheri G,Ferrigno D. Lung tumor markers in oncology practice: a study of TPA and CA125 [J]. BrJ Cancer, 2002, 87(10):1112~1118 被引量:1
  • 5[5]David O. Akt and PTEN: new diagnostic marker of non-small cell lung cancer[J].J Cell Mol Med, 2001, 5(4): 430~433 被引量:1
  • 6[6]Buccheri G, Torchio P, Ferrigno D. Clinical Equivalence of Two Cytokeratin Markers in Non-small cell lung cancer [J]. Chest,2003, 124(2): 622~632 被引量:1
  • 7[7]Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis.Comparison with the main clinical and pathological prognostic factors[J]. Tumour Biol, 2003, 24(4): 209~218 被引量:1
  • 8[8]Pollan M, Varela G, Torres A, et al. Clinical value of p53, cerbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer [J]. Int J Cancer, 2003,107(5): 781~790 被引量:1
  • 9[9]Schneider J, Peltri G, Bitterlich N, et al. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients [J]. Clin Exp Med, 2003, 2(4): 185~191 被引量:1
  • 10[10]Schneider J, Philipp M, Velcovsky HG, et al. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases[J]. Anticancer Res, 2003, 23(2A): 885~893 被引量:1

共引文献44

同被引文献9

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部